Development of upstream processes, that maximize productivity without increasing complexity, relies on the right combination of medium and feed and the ability to maintain tight control of culture conditions. In fed-batch mode, cells are initially grown in a relatively lean production medium followed by regular feed supplementation to achieve the desired product yield. This App Note presents an optimized feeding strategy and demonstrates how a new, easy-to-hydrate, single-part, pH neutral feed can support optimal cell growth and high productivity of…
Tuesday, April 5, 2022 Daily Archives
Bayer on keeping CGT acquisitions at arm’s length
Keeping biotech bolt-ons separate from its main organization is essential in retaining agility, speed, and innovation for cell and gene therapies, says Bayer’s Jens Vogel. Despite relatively few reaching commercialization, cell and gene therapies (CGTs) have become a solid part of the wider pharmaceutical landscape with numerous big firms dabbling in the sector. German biopharma giant Bayer became a serious fixture in the advanced therapy space in 2019 when it bought out cell therapy developer BlueRock Therapeutics. The following year,…